Introduction: Mycosis fungoides is a kind of malignant lymphoma arising from T cells, but primarily occurs in skin, and it is the most common type of cutaneous lymphoma. Mycosis fungoides (MF) is a rare non-Hodgkin lymphoma but the most common type of primary cutaneous T-cell lymphomas. Because of unknown etiology and mechanism, and lack of typical clinical and histophysiological manifestations, the final diagnosis of MF is currently dependent on pathology and immunohistochemistry. Subsequently, tumor staging is very important. Different approaches would be taken according to varying degrees of cutaneous and extracutaneous lesions. Computed tomography (CT) scan has been chosen to stage tumors customarily. However, CT could only provide morphological information and analyze lymphadenopathy by the size criteria.
Introduction
Mycosis fungoides (MF) is a primary cutaneous non-Hodgkin lymphoma (NHL) of T-cell origin and relatively rare disease that occurred in 0.36 per 100,000 annually. [1] MF could affect cutaneous spread and extracutaneous spread that might involve lymph nodes, skeletal sites, peripheral blood, and viscera. The staging of cutaneous spread and extracutaneous involvement has imperative implications on patient therapeutic plan and prognosis. [2] 18 F-flurodeoxyglucose positron emission tomography/computed tomography (PET/CT) has been used to evaluate stage and prognosis for variety of lymphomas. [3] Only few case reports and investigations assess the potential role of PET/CT in diagnosing and staging primary cutaneous lymphomas including MF. [4] Flurodeoxyglucose (FDG) is the most commonly used positron tracer at present, and its uptake in the malignant tumor is increasing evidently. The lesions in the early stage of MF absorb FDG slightly. It could be helpful to locate the lesion which need biopsy. Cutaneous and extracutaneous lesions in the advanced stage of MF are both FDG high uptake. We present a case of MF that was staged by 18 F-flurodeoxyglucose PET/CT, and the related literature are reviewed.
Case report

Patient information
A 62-year-old female patient was admitted to our institution on April 01, 2015 for dozens of plaques that gradually appeared on the skin of face, chest and back, upper limbs, and bilateral thigh within a year. In addition, she had a 30-year history of multiple pruritic patches on the skin all over the body.
Clinical findings
The patient's vital signs were stable at admission, and physical examination showed patches and plaques symmetrically distributed on the skin of face, trunk, upper limbs, and bilateral thigh. The maximum size of plaques was about 6 Â 6 cm 2 .
Diagnostic focus and assessment
After providing informed consent, a biopsy of a cutaneous lesion on patient's left forearm was performed. On histopathology, interstitial infiltration of lymphoid cells with stained cytoplasm and nuclear, and pathological mitotic figure could be presented (Fig. 1A ).
Immunohistochemistry showed that the dermis cells expressed CD2, CD3, CD4, and CD5 ( Fig. 1B-E ). The diagnosis of MF was 
Discussion
MF is a rare NHL but is the most frequent type of T-cell lymphomas that primarily involve the skin. It is featured by a characteristic long course of disease and T-cell malignant proliferation. Patches, infiltrated plaques, and tumors are 3 classical clinical cutaneous phases of MF which have been reported. [5] Any of these 3 phases could be the initial symptom. In addition, these 3 phases could commonly overlap or occur simultaneously. [6] Thus, MF is not easy to confirm, mainly due to the atypical clinical manifestations at a prime stage. [7] The cutaneous extension and skin involvement phase and whether involving extracutaneous lymphonode or organs are related with prognosis, [8] so accurate staging is imperative for prognosis and to help formulate appropriate treatment selections. [9] As a conventional imaging examination approach, computed tomography (CT) scan has been used to stage variety of tumors by the size criteria and only morphological information. [10] Normalsized lymphonodes involved by MF are easy to be missed by CT scans, and enlarged nonspecific inflammatory reactive lymphonodes are easy to be misdiagnosed. [11] Only few case reports mentioned the potential role of 18 F-FDG PET/CT in diagnosing primary cutaneous lymphomas such as MF. [7, 12] 18 F-FDG PET/ CT has been reported to have better sensitivity and specificity than CT alone. It may reveal the metabolism of lesions based on SUVmax. Combined with morphologic information provided by CT, 18 F-FDG PET/CT could provide more valuable information for the diagnosis and staging of MF. In addition, 18 F-FDG PET/ CT could provide a definitive localization of metabolic activity within specific lesions. [13] However, cutaneous lymphomas with some chronic skin diseases such as dermatopathic lymphadenitis could take high value 18 F-FDG has been reported. [14] 4. Conclusion
In conclusion, 18 F-FDG PET/CT could identify cutaneous and extracutaneous lesions in patients with MF. Although 18 F-FDG PET/CT could not routinely define all cutaneous and extracutaneous lesions, it could be a sensitive, accurate, valuable imaging approach for diagnosis and therapy plans, especially staging.
